Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
| Author | |
|---|---|
| Abstract | :
This study evaluated objective response and safety for the combination of granulocyte macrophage-colony stimulating factor (GM-CSF), ketoconazole, and mitoxantrone in castration-resistant prostate cancer (CRPC) patients who previously failed docetaxel-based chemotherapy. |
| Year of Publication | :
2013
|
| Journal | :
Cancer investigation
|
| Volume | :
31
|
| Issue | :
3
|
| Number of Pages | :
177-82
|
| ISSN Number | :
0735-7907
|
| URL | :
http://www.tandfonline.com/doi/full/10.3109/07357907.2013.764564
|
| DOI | :
10.3109/07357907.2013.764564
|
| Short Title | :
Cancer Invest
|
| Download citation |